




Supplementary Figure 2



Variable	N	Hazard ratio	p
Capmatinib or Tepotinib	53	Reference	
Chemoimmunotherapy	36	1.45 (0.88, 2.40)	0.1
Crizotinib	22	1.46 (0.85, 2.52)	0.2
ICI monotherapy	39	1.34 (0.82, 2.18)	0.2

	ICI monotherapy	Chemoimmunotherapy	Capmatinib or Tepotinib	Crizotinib
6-months rwPFS	41%	50%	62%	61%
12-months rwPFS	31%	30%	45%	33%
24-months rwPFS	20%	13%	25%	4%



Variable	N	Hazard ratio	p
Capmatinib or Tepotinib	53	Reference	
Chemoimmunotherapy	37	1.20 (0.69, 2.12)	0.5
Crizotinib	22	1.23 (0.67, 2.24)	0.5
ICI monotherapy	41	1.05 (0.60, 1.82)	0.9

	ICI monotherapy	Chemoimmunotherapy	Capmatinib or Tepotinib	Crizotinib
1-year OS	65%	65%	73%	77%
3-years OS	46%	31%	41%	22%
5-years OS	22%	16%	20%	11%

Supplementary Figure 2. **(A)** Real-world objective response rate (rwORR), **(B)** real-world progression-free survival (rwPFS), and **(C)** overall survival (OS) of metastatic METex14 mutant NSCLC according to detailed first-line treatment (ICI monotherapy, chemoimmunotherapy, capmatinib or tepotinib, crizotinib). The 5 patients treated with other MET TKI (3 with glesatinib, 1 with TPX-0022, 1 with APL-101) were not include.